{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T12:09:22Z","timestamp":1794917362771,"version":"4.9.1"},"reference-count":88,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T00:00:00Z","timestamp":1709078400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008856","name":"Zhejiang Provincial Health Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008856","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.heliyon.2024.e27325","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T02:04:28Z","timestamp":1709172268000},"page":"e27325","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Non-invasive diagnosis of non-alcoholic fatty liver disease: Current status and future perspective"],"prefix":"10.1016","volume":"10","author":[{"given":"Jia-Lan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Wen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8176-2714","authenticated-orcid":false,"given":"Ai-Rong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-Wu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Shan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.heliyon.2024.e27325_bib1","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/joim.13531","article-title":"Current treatment of non-alcoholic fatty liver disease","volume":"292","author":"Paternostro","year":"2022","journal-title":"J. Intern. Med."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e27325_bib2","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/dom.14322","article-title":"Nonalcoholic fatty liver disease as a metabolic disease in humans: a literature review","volume":"23","author":"Cariou","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"21","key":"10.1016\/j.heliyon.2024.e27325_bib3","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMra1503519","article-title":"Cause, Pathogenesis, and treatment of nonalcoholic steatohepatitis","volume":"377","author":"Diehl","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e27325_bib4","article-title":"A multi-society Delphi consensus statement on new fatty liver disease nomenclature","author":"Rinella","year":"2023","journal-title":"J. Hepatol."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e27325_bib5","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-Driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"issue":"Suppl","key":"10.1016\/j.heliyon.2024.e27325_bib6","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.3350\/cmh.2022.0367","article-title":"MAFLD: How is it different from NAFLD?","volume":"29","author":"Gofton","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e27325_bib7","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.cgh.2021.01.017","article-title":"On the proposed definition of metabolic-associated fatty liver disease","volume":"19","author":"Wai-Sun Wong","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e27325_bib8","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1016\/j.jhep.2023.07.021","article-title":"Can we use old NAFLD data under the new MASLD definition?","volume":"80","author":"Song","year":"2024","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e27325_bib9","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/cld.1061","article-title":"Global Epidemiology of chronic liver disease","volume":"17","author":"Cheemerla","year":"2021","journal-title":"Clin. Liver Dis."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e27325_bib10","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/hep.30254","article-title":"Burden of illness and Economic model for patients with nonalcoholic steatohepatitis in the United States","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e27325_bib11","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1016\/j.cgh.2021.12.002","article-title":"Global NAFLD prevalence: a systematic review and meta-analysis","volume":"20","author":"Le","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e27325_bib12","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e27325_bib13","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jhep.2023.03.040","article-title":"Global incidence of non-alcoholic fatty liver disease: a systematic review and meta-analysis of 63 studies and 1,201,807 persons","volume":"79","author":"Le","year":"2023","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27325_bib14","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1161\/STROKEAHA.120.030433","article-title":"Severity of nonalcoholic fatty liver disease and risk of future ischemic Stroke events","volume":"52","author":"Xu","year":"2021","journal-title":"Stroke"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e27325_bib15","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1136\/gutjnl-2021-325724","article-title":"Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort","volume":"71","author":"Simon","year":"2022","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e27325_bib16","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1093\/eurjpc\/zwab212","article-title":"Risk of cardiovascular events in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"29","author":"Alon","year":"2022","journal-title":"Eur J Prev Cardiol"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27325_bib17","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2021-000817","article-title":"Metabolic dysfunction-related liver disease as a risk factor for cancer","volume":"9","author":"Taylor","year":"2022","journal-title":"BMJ Open Gastroenterol"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e27325_bib18","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jacc.2021.11.007","article-title":"Risk of heart failure in patients with nonalcoholic fatty liver disease: JACC review topic of the week","volume":"79","author":"Mantovani","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e27325_bib19","first-page":"195","volume":"31","year":"2018","journal-title":"Chin. J. Hepatol."},{"key":"10.1016\/j.heliyon.2024.e27325_bib20","article-title":"Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future","author":"Reinson","year":"2022","journal-title":"Clin. Mol. Hepatol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e27325_bib21","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e27325_bib22","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.jhep.2019.12.008","article-title":"Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease","volume":"72","author":"Nascimbeni","year":"2020","journal-title":"J. Hepatol."},{"issue":"21","key":"10.1016\/j.heliyon.2024.e27325_bib23","first-page":"22","article-title":"Clinical and molecular biomarkers for diagnosis and staging of NAFLD","author":"Di Mauro","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e27325_bib24","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e27325_bib25","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr. Pract."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e27325_bib26","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update","volume":"75","year":"2021","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e27325_bib27","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/hep.32665","article-title":"Validation of the new 2021 EASL algorithm for the noninvasive diagnosis of advanced fibrosis in NAFLD","volume":"77","author":"Canivet","year":"2023","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27325_bib28","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/jgh.13856","article-title":"The asia-pacific working party on non-alcoholic fatty liver disease guidelines 2017-Part 2: management and special groups","volume":"33","author":"Chitturi","year":"2018","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.heliyon.2024.e27325_bib29","series-title":"Non-Alcoholic Fatty Liver Disease: Assessment and Management","article-title":"National Institute for health and care excellence: guidelines","author":"National Guideline","year":"2016"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e27325_bib30","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3350\/cmh.2021.0178","article-title":"KASL clinical practice guidelines: management of nonalcoholic fatty liver disease","volume":"27","author":"Kang","year":"2021","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.heliyon.2024.e27325_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101145","article-title":"acNASH index to diagnose nonalcoholic steatohepatitis: a prospective derivation and global validation study","volume":"41","author":"Wu","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27325_bib32","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e27325_bib33","doi-asserted-by":"crossref","DOI":"10.1038\/nutd.2016.27","article-title":"Plasma phospholipids and fatty acid composition differ between liver biopsy-proven nonalcoholic fatty liver disease and healthy subjects","volume":"6","author":"Ma","year":"2016","journal-title":"Nutr. Diabetes"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e27325_bib34","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1093\/jalm\/jfaa044","article-title":"Low-density lipoprotein (LDL)-Triglyceride and its ratio to LDL-cholesterol as diagnostic biomarkers for nonalcoholic steatohepatitis","volume":"5","author":"Fujii","year":"2020","journal-title":"J Appl Lab Med"},{"key":"10.1016\/j.heliyon.2024.e27325_bib35","doi-asserted-by":"crossref","DOI":"10.1177\/1756284820923904","article-title":"Plasma eicosanoids as noninvasive biomarkers of liver fibrosis in patients with nonalcoholic steatohepatitis","volume":"13","author":"Caussy","year":"2020","journal-title":"Therap Adv Gastroenterol"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27325_bib36","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/hep.28776","article-title":"Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease","volume":"65","author":"Ajmera","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.heliyon.2024.e27325_bib37","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/9729107","article-title":"Diagnostic value of CK-18, FGF-21, and related biomarker panel in nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"2017","author":"He","year":"2017","journal-title":"BioMed Res. Int."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e27325_bib38","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1177\/2050640619868352","article-title":"Individualized risk prediction of significant fibrosis in non-alcoholic fatty liver disease using a novel nomogram","volume":"7","author":"Zhou","year":"2019","journal-title":"United European Gastroenterol J"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e27325_bib39","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1097\/MEG.0000000000002176","article-title":"Predictive value of cytokeratin-18 fragment levels for diagnosing steatohepatitis in patients with nonalcoholic fatty liver disease","volume":"33","author":"Tada","year":"2021","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e27325_bib40","article-title":"The accuracy of serum biomarkers in the diagnosis of steatosis, fibrosis, and inflammation in patients with nonalcoholic fatty liver disease in comparison to a liver biopsy","volume":"58","author":"Mikolasevic","year":"2022","journal-title":"Medicina (Kaunas)"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e27325_bib41","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jhep.2021.09.024","article-title":"Asian perspective on NAFLD-associated HCC","volume":"76","author":"Yip","year":"2022","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27325_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2022.100873","article-title":"Diagnostic accuracy of blood biomarkers and non-invasive scores for the diagnosis of NAFLD and NASH: systematic review and meta-analysis","volume":"28","author":"Contreras","year":"2023","journal-title":"Ann. Hepatol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e27325_bib43","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jhep.2017.11.013","article-title":"Non-invasive assessment of non-alcoholic fatty liver disease: clinical prediction rules and blood-based biomarkers","volume":"68","author":"Vilar-Gomez","year":"2018","journal-title":"J. Hepatol."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e27325_bib44","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S2468-1253(20)30252-1","article-title":"A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study","volume":"5","author":"Harrison","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e27325_bib45","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","article-title":"Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD","volume":"67","author":"Hagstrom","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.heliyon.2024.e27325_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(22)00546-3","article-title":"Validation of the new 2021 EASL algorithm for the noninvasive diagnosis of advanced fibrosis in NAFLD","author":"Canivet","year":"2022","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e27325_bib47","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.23923","article-title":"Performance of the enhanced liver fibrosis test to estimate advanced fibrosis among patients with nonalcoholic fatty liver disease","volume":"4","author":"Younossi","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.heliyon.2024.e27325_bib48","article-title":"Diagnostic accuracy of enhanced liver fibrosis test for nonalcoholic steatohepatitis-related fibrosis: multicenter study","author":"Seko","year":"2022","journal-title":"Hepatol. Res."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e27325_bib49","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/jhbp.972","article-title":"Machine learning algorithm outperforms fibrosis markers in predicting significant fibrosis in biopsy-confirmed NAFLD","volume":"28","author":"Feng","year":"2021","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e27325_bib50","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/jcu.22382","article-title":"Diagnostic accuracy of hepatorenal index in the detection and grading of hepatic steatosis","volume":"44","author":"Chauhan","year":"2016","journal-title":"J. Clin. Ultrasound"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e27325_bib51","first-page":"5453","article-title":"Sonographic assessment of fatty liver: intraobserver and interobserver variability","volume":"7","author":"Cengiz","year":"2014","journal-title":"Int. J. Clin. Exp. Med."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27325_bib52","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/jcu.21994","article-title":"Sonographic hepatorenal ratio: a noninvasive method to diagnose nonalcoholic steatosis","volume":"41","author":"Borges","year":"2013","journal-title":"J. Clin. Ultrasound"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e27325_bib53","doi-asserted-by":"crossref","first-page":"W168","DOI":"10.2214\/AJR.16.16726","article-title":"A pilot comparative study of quantitative ultrasound, conventional ultrasound, and MRI for predicting histology-determined steatosis grade in adult nonalcoholic fatty liver disease","volume":"208","author":"Paige","year":"2017","journal-title":"AJR Am. J. Roentgenol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27325_bib54","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ultrasmedbio.2015.08.008","article-title":"Liver steatosis assessed by controlled attenuation parameter (CAP) measured with the XL probe of the FibroScan: a pilot study assessing diagnostic accuracy","volume":"42","author":"Sasso","year":"2016","journal-title":"Ultrasound Med. Biol."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e27325_bib55","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1111\/jgh.12557","article-title":"Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease","volume":"29","author":"Chan","year":"2014","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"39","key":"10.1016\/j.heliyon.2024.e27325_bib56","article-title":"Feasibility and Efficacy of Transient Elastography using the XL probe to diagnose liver fibrosis and cirrhosis: a meta-analysis","volume":"97","author":"Xia","year":"2018","journal-title":"Medicine (Baltim.)"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e27325_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics13040788","article-title":"How to identify advanced fibrosis in adult patients with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) using ultrasound elastography-A review of the literature and proposed multistep approach","volume":"13","author":"Taru","year":"2023","journal-title":"Diagnostics"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e27325_bib58","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1111\/liv.12809","article-title":"Impact of skin capsular distance on the performance of controlled attenuation parameter in patients with chronic liver disease","volume":"35","author":"Shen","year":"2015","journal-title":"Liver Int."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27325_bib59","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.cgh.2018.04.043","article-title":"Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease","volume":"17","author":"Siddiqui","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27325_bib60","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s00535-019-01626-1","article-title":"Diagnostic accuracy of combined biomarker measurements and vibration-controlled transient elastography (VCTE) for predicting fibrosis stage of non-alcoholic fatty liver disease","volume":"55","author":"Shima","year":"2020","journal-title":"J. Gastroenterol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e27325_bib61","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S2468-1253(19)30383-8","article-title":"FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study","volume":"5","author":"Newsome","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e27325_bib62","first-page":"1288","article-title":"Diagnostic accuracy of fiborscan-AST score in nonalcoholic steatohepatitis with significant activity and fibrosis","volume":"38","author":"Zhao","year":"2022","journal-title":"J Clin Hepatol"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e27325_bib63","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/liv.13058","article-title":"Prospective comparison of magnetic resonance imaging to transient elastography and serum markers for liver fibrosis detection","volume":"36","author":"Dyvorne","year":"2016","journal-title":"Liver Int."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e27325_bib64","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1053\/j.gastro.2016.10.026","article-title":"Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease","volume":"152","author":"Park","year":"2017","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e27325_bib65","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1080\/00365521.2020.1786599","article-title":"Biomarkers of liver fibrosis: prospective comparison of multimodal magnetic resonance, serum algorithms and transient elastography","volume":"55","author":"Forsgren","year":"2020","journal-title":"Scand. J. Gastroenterol."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e27325_bib66","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/ajg.2016.65","article-title":"Novel 3D magnetic resonance elastography for the noninvasive diagnosis of advanced fibrosis in NAFLD: a prospective study","volume":"111","author":"Loomba","year":"2016","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.heliyon.2024.e27325_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101167","article-title":"Imaging biomarkers of NAFLD, NASH, and fibrosis","volume":"50","author":"Ajmera","year":"2021","journal-title":"Mol Metab"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e27325_bib68","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.32145","article-title":"Magnetic resonance elastography plus Fibrosis-4 versus FibroScan-aspartate aminotransferase in detection of candidates for pharmacological treatment of NASH-related fibrosis","volume":"75","author":"Tamaki","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.heliyon.2024.e27325_bib69","doi-asserted-by":"crossref","DOI":"10.1038\/srep31421","article-title":"Imaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver disease","volume":"6","author":"Gallego-Duran","year":"2016","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e27325_bib70","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jhep.2016.06.005","article-title":"MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: clinical trials to clinical practice","volume":"65","author":"Dulai","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.heliyon.2024.e27325_bib71","article-title":"Correlations between MRI biomarkers PDFF and cT1 with histopathological features of non-alcoholic steatohepatitis","volume":"11","author":"Dennis","year":"2020","journal-title":"Front. Endocrinol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e27325_bib72","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1053\/j.gastro.2018.04.014","article-title":"Magnetic resonance imaging proton density fat fraction associates with progression of fibrosis in patients with nonalcoholic fatty liver disease","volume":"155","author":"Ajmera","year":"2018","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e27325_bib73","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.jhep.2021.11.012","article-title":"MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis","volume":"76","author":"Noureddin","year":"2022","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27325_bib74","first-page":"443","article-title":"Genome-wide analysis of DNA methylation in human peripheral leukocytes identifies potential biomarkers of nonalcoholic fatty liver disease","volume":"42","author":"Zhang","year":"2018","journal-title":"Int. J. Mol. Med."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e27325_bib75","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1194\/jlr.P056002","article-title":"Biomarkers of NAFLD progression: a lipidomics approach to an epidemic","volume":"56","author":"Gorden","year":"2015","journal-title":"J. Lipid Res."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27325_bib76","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1194\/jlr.P055640","article-title":"Polyunsaturated fatty acid metabolites as novel lipidomic biomarkers for noninvasive diagnosis of nonalcoholic steatohepatitis","volume":"56","author":"Loomba","year":"2015","journal-title":"J. Lipid Res."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e27325_bib77","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/hep4.1188","article-title":"Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: results from discovery and validation cohorts","volume":"2","author":"Mayo","year":"2018","journal-title":"Hepatol Commun"},{"issue":"10","key":"10.1016\/j.heliyon.2024.e27325_bib78","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1136\/gutjnl-2018-317584","article-title":"Serum metabolites detect the presence of advanced fibrosis in derivation and validation cohorts of patients with non-alcoholic fatty liver disease","volume":"68","author":"Caussy","year":"2019","journal-title":"Gut"},{"issue":"10","key":"10.1016\/j.heliyon.2024.e27325_bib79","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1111\/apt.16066","article-title":"Circulating lipidomic alterations in obese and non-obese subjects with non-alcoholic fatty liver disease","volume":"52","author":"Jung","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e27325_bib80","doi-asserted-by":"crossref","first-page":"e784","DOI":"10.1097\/TXD.0000000000001227","article-title":"Utility of metabolomic biomarkers to identify nonalcoholic fatty liver disease in liver transplant recipients","volume":"7","author":"Mowry","year":"2021","journal-title":"Transplant Direct"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e27325_bib81","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11306-020-01756-1","article-title":"Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis","volume":"17","author":"Masarone","year":"2021","journal-title":"Metabolomics"},{"key":"10.1016\/j.heliyon.2024.e27325_bib82","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.683250","article-title":"Adiponectin, leptin, and IGF-1 are useful diagnostic and stratification biomarkers of NAFLD","volume":"8","author":"Marques","year":"2021","journal-title":"Front. Med."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e27325_bib83","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1111\/liv.14167","article-title":"Serum coding and non-coding RNAs as biomarkers of NAFLD and fibrosis severity","volume":"39","author":"Di Mauro","year":"2019","journal-title":"Liver Int."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e27325_bib84","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0142661","article-title":"Performance of serum microRNAs -122, -192 and -21 as biomarkers in patients with non-alcoholic steatohepatitis","volume":"10","author":"Becker","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.heliyon.2024.e27325_bib85","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/2096161","article-title":"Circulating miRNAs as novel diagnostic biomarkers in nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"2019","author":"Cai","year":"2019","journal-title":"Can J Gastroenterol Hepatol"},{"key":"10.1016\/j.heliyon.2024.e27325_bib86","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.2147\/DMSO.S231321","article-title":"The circulating micro-RNAs (-122, -34a and -99a) as predictive biomarkers for non-alcoholic fatty liver diseases","volume":"12","author":"Hendy","year":"2019","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e27325_bib87","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/hep4.1670","article-title":"SOMAscan proteomics identifies serum biomarkers associated with liver fibrosis in patients with NASH","volume":"5","author":"Luo","year":"2021","journal-title":"Hepatol Commun"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27325_bib88","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20190395","article-title":"Proteomic screening of plasma identifies potential noninvasive biomarkers associated with significant\/advanced fibrosis in patients with nonalcoholic fatty liver disease","volume":"40","author":"Hou","year":"2020","journal-title":"Biosci. Rep."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024033565?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024033565?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T22:07:48Z","timestamp":1759961268000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024033565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":88,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2405844024033565"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e27325","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-invasive diagnosis of non-alcoholic fatty liver disease: Current status and future perspective","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e27325","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e27325"}}